Stock News•3 weeks ago
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
Novo Nordisk launched Awiqli in the U.S., the first once-weekly basal insulin, adding a new growth avenue beyond its pressured GLP-1 franchise.
MarketLens
Novo Nordisk's Hemophilia Win Can't Outrun GLP-1 Headwinds
2 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Why Did Novo Nordisk Stock Plummet Recently
6 months ago
Category
You may also like
Stock News•1 months ago
Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America
Novo Nordisk's CEO sees a 'long runway' for weight-loss drugs as GLP-1 adoption remains early, citing potential to slash U.S. health care costs and boost productivity.
Stock News•1 months ago
Novo Nordisk Raises Earnings Guidance. The Stock Sinks.
Novo Nordisk raised its earnings guidance, yet shares sank, as investors weighed reliance on semaglutide (Wegovy/Ozempic) for growth. The company lifted outlook after strong demand, but concerns over ...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•2 hours ago
Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.
Stock News•2 hours ago
Viral AI Dommer Tweet: Engineered Panic?
Stock News•3 hours ago
Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.
Stock News•4 hours ago
Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.
Stock News•6 hours ago